Method for differentially diagnosing ACTH-dependent Cushing's syndrome
US-9829495-B2 · Nov 28, 2017 · US
Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12226412B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12226412-B2 |
| Application number | US-202318121694-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 15, 2023 |
| Priority date | May 25, 2012 |
| Publication date | Feb 18, 2025 |
| Grant date | Feb 18, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides heteroaryl ketone fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators, including their use for treating amyotrophic lateral sclerosis (ALS).
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a disorder selected from hyperglycemia, diabetes, cardiovascular disease, hypertension, depression, major psychotic depression, and Alzheimer's disease, the method comprising administering to a subject in need thereof, a therapeutically effective amount of a glucocorticoid receptor modulator (GRM) compound, thereby treating the subject suffering from, or suspected of suffering from, hyperglycemia, diabetes, cardiovascular disease, hypertension, depression, major psychotic depression, or Alzheimer's disease, wherein said GRM compound is selected from (R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4.4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridine-2-yl)methanone, having the formula: (R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl)sulfonyl)-4,4a, 5,6,7,8-hexahydro-1-H-pyrazolo[3,4-g]isoquinolin-4a-yl)(pyridin-2-yl)methanone, having the formula: and pharmaceutically acceptable salts thereof; and (R)-(1-(4-fluorophenyl)-6-((2-methyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone, having the formula 2. The method of claim 1 , wherein said disorder is hyperglycemia. 3. The method of claim 1 , wherein said disorder is diabetes. 4. The method of claim 1 , wherein said disorder is cardiovascular disease. 5. The method of claim 1 , wherein said disorder is hypertension. 6. The method of claim 1 , wherein said disorder is depression. 7. The method of claim 1 , wherein said disorder is major psychotic depression. 8. The method of claim 1 , wherein said disorder is Alzheimer's disease.
Assignees
Inventors
Classifications
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title
Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids · CPC title
- A61K31/5383Primary
ortho- or peri-condensed with heterocyclic ring systems · CPC title
Ortho-condensed systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12226412B2 cover?
- The present invention provides heteroaryl ketone fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators, including their use for treating amyotrophic lateral sclerosis (ALS).
- Who is the assignee on this patent?
- Corcept Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/5383. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).